BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Society of Cannabis Clinicians - ECPv6.15.15//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.cannabisclinicians.org
X-WR-CALDESC:Events for Society of Cannabis Clinicians
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Denver
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20240310T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20241103T080000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20250309T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20251102T080000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20260308T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20261101T080000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20240310T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20241103T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20260308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20261101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20270314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20271107T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Denver:20251024T130000
DTEND;TZID=America/Denver:20251025T170000
DTSTAMP:20260607T102245
CREATED:20250206T151618Z
LAST-MODIFIED:20250721T161610Z
UID:10000180-1761310800-1761411600@www.cannabisclinicians.org
SUMMARY:SCC 3rd Annual Medical Cannabis Conference
DESCRIPTION:  \nSCC 3rd Annual Medical Cannabis Conference\nOctober 24 (1pm Mountain Time) – October 25 (5pm Mountain Time) \nThis year’s two-day event will bring together the brightest minds and leading experts across the medical cannabis industry for a two days of education\, innovation\, and collaboration. Whether you’re a healthcare professional\, patient advocate\, researcher\, or industry leader\, this event is designed to empower you with the latest insights\, research\, and best practices in medical cannabis. \nWhat to Expect at MedCannCon25: \n\nKeynote presentations from renowned medical cannabis experts\nPanel discussions on cutting-edge research\, patient care\, and industry trends\nNetworking opportunities with professionals and advocates in the field\nExhibitors from across the industry\nAnd more!\n\nDetails \nWhere: Tivoli Turnhall at Auraria Campus (Denver\, CO)\nWhen: October 24-25\, 2025 \nRegistration Now Open! \nStay tuned for early bird discounts and exclusive opportunities to secure your spot at this premier event. \nWe can’t wait to see you in Denver for what promises to be our most impactful MedCannCon yet! Together\, we can continue to advance education\, advocacy\, and access in the medical cannabis community. \nRegister
URL:https://www.cannabisclinicians.org/event/scc-3rd-annual-medical-cannabis-conference/
ATTACH;FMTTYPE=image/png:https://www.cannabisclinicians.org/wp-content/uploads/2025/04/Medcancon25-Denver-web-banner-01-res-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20251218T090000
DTEND;TZID=America/Los_Angeles:20251218T100000
DTSTAMP:20260607T102245
CREATED:20251214T153654Z
LAST-MODIFIED:20251224T154459Z
UID:10000188-1766048400-1766052000@www.cannabisclinicians.org
SUMMARY:A Century of Advocacy & Care: Experts Respond to Federal Hemp THC Limits
DESCRIPTION:Experts Discuss New Regulatory Pathways \nThree of the nation’s leading cannabis advocacy and patient-care organizations—the National Organization for the Reform of Marijuana Laws (NORML\, founded 1970)\, the Society of Cannabis Clinicians (SCC\, founded 1999)\, and the Marijuana Policy Project (MPP\, founded 1995)—are coming together for a timely public webinar in response to recent federal changes impacting hemp-derived THC. With over a century of combined experience advancing sensible cannabis policy\, patient protections\, and evidence-informed clinical care\, this panel will offer a clear\, grounded conversation about what’s changing\, what it means\, and what comes next. \nEach organization will share a concise 10–15 minute recap of key highlights and takeaways from their recent briefings and community updates\, followed by a moderated Q&A panel where participants can ask questions and hear multiple perspectives in one place. \nAttendees can expect: \n\nPlain-language context on the federal hemp THC limits and their significance.\nPractical implications for patient access\, product availability\, safety\, and counseling.\nAdvocacy priorities and consumer-facing guidance from each organization.\nA collaborative\, solutions-oriented discussion to guide collective action in 2026.\nJoin us for an informed\, community-centered conversation that reflects the strength of our diversity—different angles\, complementary expertise\, and a shared commitment to responsible policy and patient care.\n\nRegister
URL:https://www.cannabisclinicians.org/event/a-century-of-advocacy-care-experts-respond-to-federal-hemp-thc-limits/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20251218T110000
DTEND;TZID=America/Los_Angeles:20251218T120000
DTSTAMP:20260607T102245
CREATED:20251214T153022Z
LAST-MODIFIED:20251224T153254Z
UID:10000187-1766055600-1766059200@www.cannabisclinicians.org
SUMMARY:Rooted in Evidence: SCC’s Holiday Research Showcase
DESCRIPTION:Join the Society of Cannabis Clinicians for a special end-of-year webinar and festive social gathering—ugly Christmas sweaters encouraged. \nWe’ll be unveiling our latest project\, which tackles one of the biggest misunderstandings in modern medicine: Rooted in Evidence: Cannabis\, Pharmaceuticals\, and the Case for Reform. \nThis session breaks down why botanical\, whole-plant therapeutics fundamentally don’t fit into the FDA’s traditional pharmaceutical pathway\, how this mismatch has shaped policy and clinical access\, and why the limitations of the pharma framework do not diminish the legitimacy\, efficacy\, or scientific rigor of cannabis medicine. \nYou’ll learn: \nHow the unique complexity of whole-plant cannabis challenges single-compound pharmaceutical standards\nWhy the FDA drug-development pathway is structurally incompatible with multi-molecule botanicals\nWhat this means for research\, evidence generation\, clinical practice\, and patient access\nHow SCC’s new project provides a roadmap for responsible clinical integration outside the pharmaceutical paradigm \nAfter the presentation\, stay for our virtual Ugly Christmas Sweater Social where clinicians\, researchers\, and advocates can connect\, share insights\, and celebrate the close of another transformational year in cannabis medicine. \nKnowledge\, community\, and questionable holiday fashion—all in one event. \n*Open to SCC members and the broader medical cannabis community.* \nRegister
URL:https://www.cannabisclinicians.org/event/rooted-in-evidence-sccs-holiday-research-showcase/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260106T090000
DTEND;TZID=America/Los_Angeles:20260106T100000
DTSTAMP:20260607T102245
CREATED:20251224T155741Z
LAST-MODIFIED:20251224T155741Z
UID:10000189-1767690000-1767693600@www.cannabisclinicians.org
SUMMARY:January Journal Club - A Puff Before a Pour: Dose-Dependent Effects of Cannabis on Drinking (Host: Jahan Marcu @ Cerium)
DESCRIPTION:About \nA Puff Before a Pour: Dose-Dependent Effects of Cannabis on Drinking \nEvent Description: \nThis month’s journal club will examine a landmark randomized controlled crossover trial exploring how smoked cannabis affects alcohol craving and consumption under controlled laboratory conditions. With the rise of THC beverages\, “Cali sober” trends\, and increasing co-use of cannabis and alcohol\, this study provides some of the strongest causal evidence to date on whether THC increases or decreases drinking. We will review the study’s design\, outcomes\, and implications for clinical practice\, harm-reduction counseling\, and public health messaging. \nKey takeaway: Smoking cannabis with THC (3.1% and 7.2%) significantly reduced alcohol consumption by 19–27% compared to placebo\, with nuanced effects on craving and urge. \nFeatured Article: \nMetrik J\, Aston ER\, Gunn RL\, Swift R\, MacKillop J\, Kahler CW.\nAcute Effects of Cannabis on Alcohol Craving and Consumption: A Randomized Controlled Crossover Trial. American Journal of Psychiatry. 2025; XX:1–9. \nDOI: TBA. \nSpeakers: \nPhil Molloy\, MD – Clinical education expert\nTeresa Simon\, MPH – Public health epidemiologist\nLen Kamen\, MD – Clinical pain specialist\nJahan Marcu\, PhD – Cannabis researcher \nRegister
URL:https://www.cannabisclinicians.org/event/january-journal-club-a-puff-before-a-pour-dose-dependent-effects-of-cannabis-on-drinking-host-jahan-marcu-cerium/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260108T090000
DTEND;TZID=America/Los_Angeles:20260108T100000
DTSTAMP:20260607T102245
CREATED:20251215T160108Z
LAST-MODIFIED:20251224T161615Z
UID:10000190-1767862800-1767866400@www.cannabisclinicians.org
SUMMARY:SCC CannaConnect Roundtable: Patient-Reported Outcomes (January)
DESCRIPTION:About \nWelcome to our members-only monthly event series\, CannaConnect Roundtable! \nThis month is hosted by E.R.I.C. Cancer Playbook\, powered by Whole Health Oncology Institute on the topic of patient-reported outcomes. \nPatient-reported outcomes (PROs)—what patients tell us about their symptoms\, function\, and quality of life—are transforming how we evaluate cancer care and integrative therapies\, including medical cannabis. PROs can capture real-world benefits and harms that often don’t show up in traditional clinician-reported measures or survival endpoints\, and they are increasingly used alongside randomized controlled trials (RCTs) to guide care. \nThis interactive discussion hour is designed for clinicians\, researchers\, and patient advocates who want to use patient voice and real-world data to inform safer\, more effective\, and more person-centered cannabis care in oncology. \nEach month of CannaConnect is hosted by a member of the SCC and will offer an interactive blend of networking\, clinical case discussions\, and the latest in cannabis news. You are invited to come connect with fellow SCC members\, find or offer mentorship\, share insights on clinical practices\, and welcome new members to our thriving community. \nThank you for being part of the Society! \nRegister
URL:https://www.cannabisclinicians.org/event/scc-cannaconnect-roundtable-patient-reported-outcomes-january/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260304T090000
DTEND;TZID=America/Los_Angeles:20260304T100000
DTSTAMP:20260607T102245
CREATED:20251215T161533Z
LAST-MODIFIED:20251224T161615Z
UID:10000191-1772614800-1772618400@www.cannabisclinicians.org
SUMMARY:SCC Quarterly Meeting: Leveraging Social Science for Social Progress on Psychedelics (Abel Gustafson\, PhD & Matt Goldberg\, PhD)
DESCRIPTION:About \nPsychedelic therapies are becoming more visible in both clinical research and public discourse\, and patients often look to cannabis clinicians for trustworthy\, evidence-based insights. While cannabis and psychedelics are distinct modalities\, they share overlapping patient populations\, therapeutic goals\, and sociopolitical challenges. As these treatments gain momentum\, clinicians must be prepared to discuss them responsibly\, dispel common myths\, and stay informed about emerging evidence. In alignment with the SCC’s mission to share clinical knowledge and promote best practices in cannabinoid medicine\, this session offers essential context to help clinicians navigate this rapidly evolving landscape. \nDescription:\nThere has been a significant resurgence in clinical and public interest in the ability of psychedelics to treat mental illness and generate meaningful personal experiences. However\, there are still formidable barriers in public perception that could thwart progress in policy\, research\, and therapeutic uses. These barriers include people’s beliefs and (mis)understanding of psychedelics\, persistent myths about them\, and a lack of understanding of their uses and benefits. XandY\, an independent research and strategy firm\, conducted a nationally-representative study of the US public to understand how Americans think about psychedelics and which policies they support regarding their use. In this presentation\, XandY co-founders will present those findings and discuss strategies for designing communication efforts that can cultivate public support for psychedelic research\, therapies\, and decriminalization in the United States. \nBios: \nMatthew Goldberg\, Ph.D.\nDr. Matthew Goldberg is one of the world’s leading scientific experts on persuasion\, human behavior\, and public opinion. He has developed custom research insights for tech companies\, media companies\, political figures\, and nonprofits\, and has published dozens of peer-reviewed scientific studies. He earned his Ph.D. in Social Psychology and is a faculty research scientist at Yale University. \nAbel Gustafson\, Ph.D.\nDr. Abel Gustafson is one of the world’s leading scientific experts on social psychology and communication strategy. He has provided research solutions and strategic consulting for multi-national corporations\, tech startups\, media networks\, political figures\, and NGOs\, and has published dozens of peer-reviewed scientific studies. After earning his Ph.D.\, he joined Yale University to conduct research on communication strategies related to science\, sustainability\, and emerging tech. He is a professor of public relations at the University of Cincinnati. \nRegister
URL:https://www.cannabisclinicians.org/event/scc-quarterly-meeting-leveraging-social-science-for-social-progress-on-psychedelics-abel-gustafson-phd-matt-goldberg-phd/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260624T090000
DTEND;TZID=America/Los_Angeles:20260624T100000
DTSTAMP:20260607T102245
CREATED:20251215T162102Z
LAST-MODIFIED:20251224T162130Z
UID:10000192-1782291600-1782295200@www.cannabisclinicians.org
SUMMARY:SCC Quarterly Meeting: Navigating Integrative Cancer Care: Cannabis\, Psychedelics & Supportive Therapies (Stacy D’Andre\, MD\, Mayo Clinic)
DESCRIPTION:About \nJoin us for an insightful presentation by Dr. Stacy D’Andre\, a board‐certified oncologist at Mayo Clinic with a dedicated focus on integrative oncology\, including the safe and evidence‐informed use of medical cannabis and medicinal mushrooms. \nIn this session\, Dr. D’Andre will: \n\nProvide an update on her recent research efforts in medical cannabis for oncology‐related symptom management—such as her pilot randomized placebo‐controlled trial of topical cannabidiol for chemotherapy‐induced neuropathy.\nExplore emerging work and considerations around psychedelic therapies in the context of cancer care and supportive medicine—highlighting the overlap in patient populations\, clinical questions\, and integrative care frameworks.\nDiscuss the practical implications for clinicians: how to address patient inquiries about cannabis or psychedelic‐adjunctive therapies\, integrate conversations into care plans\, evaluate the growing body of evidence\, and incorporate best practices in an evolving regulatory and clinical landscape.\n\nRegister
URL:https://www.cannabisclinicians.org/event/scc-quarterly-meeting-navigating-integrative-cancer-care-cannabis-psychedelics-supportive-therapies-stacy-dandre-md-mayo-clinic/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260902T090000
DTEND;TZID=America/Los_Angeles:20260902T100000
DTSTAMP:20260607T102245
CREATED:20251215T162441Z
LAST-MODIFIED:20251224T162505Z
UID:10000193-1788339600-1788343200@www.cannabisclinicians.org
SUMMARY:SCC Quarterly Meeting: Emerging Insights from Alzheimer’s Research (Duncan Mackie\, PhD)
DESCRIPTION:About \nSpeaker: \nDuncan Mackie\, PhD\, Director of Pharmacology & Experimental Therapeutics\, MedPharm Holdings \nEvent Description: \nAlzheimer’s disease remains one of the most challenging neurodegenerative conditions to treat\, and interest is growing in how cannabinoids might modulate key pathways involved in its progression. MedPharm Holdings\, a Denver-based cannabis research and formulation development company\, has focused its R&D program on neuropharmacology—particularly Alzheimer’s disease and dementia—leveraging one of Colorado’s first cannabis research licenses and a federal Schedule I research license to systematically study cannabis-derived compounds. \nIn this presentation\, Dr. Duncan Mackie will share emerging findings from his ongoing work conducted in collaboration with academic partners through Colorado State University’s Institute of Cannabis Research. This project investigates how specific phytocannabinoids may influence Alzheimer’s-related mechanisms\, with an emphasis on neuroinflammation\, neuronal health\, and potential disease-modifying pathways. \nBio: \nDr. Duncan I. Mackie is the Director of Pharmacology and Experimental Therapeutics at Bud & Mary’s\, where he leads innovative research in drug discovery\, cellular and molecular biology\, and G-protein-coupled receptor (GPCR) pharmacology to explore the therapeutic potential of cannabinoids. His work focuses on their interactions with the endocannabinoid system\, with the goal of identifying novel drug targets and developing new treatments for complex diseases. He is one of only a small number of investigators in the United States to hold a Federal DEA Schedule I Researcher license to study cannabis and cannabinoids\, which uniquely positions his laboratory to advance translational research in this rapidly evolving field. \nA recognized leader in cannabis research\, Dr. Mackie has established a rigorous\, externally funded research program focused on the role of the endocannabinoid system in modulating immune function during the onset and progression of neurodegenerative diseases such as Alzheimer’s and Parkinson’s. His wide-ranging research interests span all areas of cannabis and cannabinoid research\, from development of analytical and regulatory testing methods\, investigations into label compliance and quality standards\, cellular and mechanistic studies of cannabinoid signaling\, creation of biosensors and high-throughput pharmacology assays\, and the design of advanced preclinical models of neuroinflammation. He is also actively involved in clinical translation research\, contributing to FDA-approved clinical trials. \nDr. Mackie has published in leading journals including the Proceedings of the National Academy of Sciences and Journal of Experimental Medicine\, and he is an inventor on multiple patents arising from his discoveries. He is a sought-after speaker and lecturer on cannabis and science-related topics at various conferences and events\, and he mentors students and trainees through his role as a Graduate Faculty member in the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of Colorado Anschutz Medical Campus. Additionally\, he is the Chair of the Cannabis Program Advisory Board at the Community College of Denver and as an Associate Editor for the Journal of Cannabis Research\, reflecting his dedication to advancing cannabis science through both education and scholarly publishing. \nHe earned his B.S. in Mathematics from the University of the Cumberlands and his Ph.D. in Medicinal and Natural Products Chemistry from the Pharmaceutical Sciences and Experimental Therapeutics Department at the University of Iowa School of Pharmacy and completed his postdoctoral research in the Department of Cellular Biology and Physiology at the University of North Carolina-Chapel Hill. \nRegister
URL:https://www.cannabisclinicians.org/event/scc-quarterly-meeting-emerging-insights-from-alzheimers-research-duncan-mackie-phd/
END:VEVENT
END:VCALENDAR